PWA
ZYNE

PCG Wealth Advisors’s Zynerba Pharmaceuticals, Inc ZYNE Stock Holding History

PCG Wealth Advisors’s Portfolio ZYNE Stock Details ZYNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-15,200
Closed -$12K – 154
2022
Q3 		$12K Buy
+15,200
New +$17.2K ﹤0.01% 136
2022
Q1 		– Sell
-11,900
Closed -$34K – 94
2021
Q4 		$34K Buy
+11,900
New +$44K 0.02% 79

Other funds holding ZYNE

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EMG
ETF Managers Group Summit, New Jersey $3.1B AUM 17.12% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
PCM
Penserra Capital Management Orinda, California $8.52B AUM 37.76% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
IEFM
IQ EQ Fund Management Dublin 2, Ireland $1.32B AUM 31.52% 1-Year Est. Return

PCG Wealth Advisors's ZYNE Position: Q4 2022 in Review

PCG Wealth Advisors sold out of Zynerba Pharmaceuticals, Inc (ZYNE) in Q4 2022, closing a stake of 15,200 shares — an estimated $12K sold.

PCG Wealth Advisors first reported a position in ZYNE in Q4 2021 and held it in 2 quarters. The position peaked at $34K in Q4 2021. 50 funds tracked by Wall St. Rank hold ZYNE as of Q4 2022.

  • PCG Wealth Advisors reported no remaining Zynerba Pharmaceuticals, Inc position as of Q4 2022 after selling out during the quarter.
  • PCG Wealth Advisors sold 15,200 Zynerba Pharmaceuticals, Inc shares in Q4 2022, an estimated $12K.
  • PCG Wealth Advisors first reported a position in Zynerba Pharmaceuticals, Inc in Q4 2021 and held it in 2 quarters.
  • PCG Wealth Advisors's Zynerba Pharmaceuticals, Inc position peaked at $34K in Q4 2021.
  • 50 funds tracked by Wall St. Rank held Zynerba Pharmaceuticals, Inc as of Q4 2022.

Based on PCG Wealth Advisors's 13F filing for Q4 2022, filed 13 Feb 2023.